Phase I Study With Prexasertib and LY3300054 in Ovarian Cancer

Claire Manuszak, BS, research technician, Center for Immuno-Oncology Immune Assessment Laboratory, Dana-Farber Cancer Institute, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.

Investigators evaluated the CHK1 inhibitor and the PD-L1 inhibitor in 15 patients with advanced solid tumors, including those with high-grade serous ovarian cancer. Prexasertib is a checkpoint kinase I inhibitor and LY3300054 is a monoclonal antibody that targets PD-L1. In the single-center study, patients received the combination intravenously on days 1 and 15, says Manuszak. Patient samples were also collected and evaluated for activation and checkpoint markers.

The results, which were presented at the 2019 SITC Annual Meeting, showed that 7 patients achieved a response to the combination, says Manuszak, which is encouraging for such a difficult-to-treat patient population. The study is expected to complete in April 2024.